A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection
To examine, in HIV-infected patients, the safety of allogeneic lymphocyte transfer (i.e., infusion of white blood cells taken from an HIV-negative parent, sibling, or adult offspring who has a compatible blood type). To measure the distribution and survival of allogeneic lymphocytes in the circulation of HIV-infected patients, and to determine whether their infusion results in enhanced immunity. To determine whether enhanced immunity is passively transferred or actively induced.
There is evidence that periodic infusion of allogeneic lymphocytes obtained from the peripheral blood of HLA-matched HIV-1 seronegative siblings of patients with AIDS can, in some instances, restore the number of circulating CD4+ lymphocytes. However, more controlled studies are needed to better quantitate the immunologic reconstitution seen with this type of therapy.
調査の概要
詳細な説明
There is evidence that periodic infusion of allogeneic lymphocytes obtained from the peripheral blood of HLA-matched HIV-1 seronegative siblings of patients with AIDS can, in some instances, restore the number of circulating CD4+ lymphocytes. However, more controlled studies are needed to better quantitate the immunologic reconstitution seen with this type of therapy.
Lymphocytes obtained by leukapheresis from a healthy, HIV-negative parent, sibling, or adult offspring of the HIV-infected patient are infused at day 0 and at weeks 4 and 8. A small portion of the lymphocytes obtained at day 0 will be radiolabeled prior to infusion, and two total body scans will be performed. Patients also undergo two tonsillar biopsies. Patients are followed weekly for 16 weeks, then by telephone periodically for 3 years (at 1 year, 2 years, 2.5 years, and 3 years).
研究の種類
入学
段階
- 適用できない
連絡先と場所
研究場所
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- Univ Hosp of Cleveland / Case Western Reserve Univ
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
Concurrent Medication:
Required:
- Stable antiretroviral therapy.
Allowed:
- Maintenance therapy for a controlled opportunistic infection.
Patients must have:
- HIV infection.
- CD4 count 50-200 cells/mm3.
- No ongoing major opportunistic infections.
- Been on stable antiretroviral therapy for the past 2 months.
- Tonsils present.
- Life expectancy greater than 6 months.
- An HLA-single haplotype matched, single haplotype mismatched parent, sibling, or adult offspring who is ABO, Rh compatible to serve as an HIV-negative lymphocyte donor.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Lymphoma or other malignancy requiring chemotherapy.
- Bleeding disorder that would preclude a tonsillar biopsy.
- Antibody on donor/recipient lymphocyte reactive antibody assay.
Donors with the following symptoms or conditions are excluded:
- Medical condition that would endanger health of donor or recipient.
- Failure to meet established donor standards on blood screening tests.
- CMV seropositivity if the patient (recipient) is CMV seronegative.
- Pregnancy.
Concurrent Medication:
Excluded:
- GM-CSF or G-CSF.
- Any investigational drug.
- Immunomodulators (such as interferon, steroids, topical corticosteroids, thalidomide, pentoxifylline, IL-2).
- Nonsteroidal anti-inflammatory drugs.
- Aspirin.
Prior Treatment:
Excluded:
- Blood transfusion within the past 2 months.
Required:
- Stable antiretroviral therapy for at least 2 months prior to study entry.
Active substance abuse.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
協力者と研究者
捜査官
- スタディチェア：Lee E
- スタディチェア：Deyton L
出版物と役立つリンク
研究記録日
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- DATRI 016
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。